GSK stopped two UTI an­tibi­ot­ic tri­als ear­ly af­ter meet­ing ef­fi­ca­cy end­points. Now it’s shar­ing the full da­ta

At a con­fer­ence in Copen­hagen, GSK shared the full da­ta on Sat­ur­day from two Phase III tri­als of its new an­tibi­ot­ic for uri­nary tract in­fec­tions.

In No­vem­ber, the phar­ma com­pa­ny had an­nounced that it had stopped those two tri­als of gepoti­dacin ear­ly af­ter an in­de­pen­dent re­view group flagged that the tri­als had al­ready met their pri­ma­ry end­points. Both tri­als were set up for non­in­fe­ri­or­i­ty com­pared to ni­tro­fu­ran­toin, which is a first-line op­tion for un­com­pli­cat­ed UTIs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER